

# Frequency of psychiatric disorders in blepharospasm does not differ from hemifacial spasm

Dias FM, Doyle F, Kummer A, Cardoso F, Fontenelle LF, Teixeira AL. Frequency of psychiatric disorders in blepharospasm does not differ from hemifacial spasm.

**Objective:** To compare the frequency of psychiatric disorders and the severity of psychiatric symptoms between patients with blepharospasm (BS) and hemifacial spasm (HS).

**Methods:** BS is a type of primary focal dystonia characterised by recurrent and involuntary eye blinking. HS is a condition with different pathophysiology but similar clinical phenotype. Twenty-two patients with BS and 29 patients with HS participated in this study. They underwent a comprehensive psychiatric evaluation that included a structured clinical interview for current psychiatric diagnosis according to *Diagnostic Statistical Manual, fourth edition* (DSM-IV) (MINI-Plus) and psychometric scales, including the Yale-Brown Obsessive-Compulsive Scale (YBOCS), the Beck Depression Inventory (BDI), the Hamilton Rating Scale for Depression (HRSD), the Hamilton Anxiety Scale (HAS) and the Liebowitz Social Anxiety Scale (LSAS).

**Results:** BS and HS groups did not differ in most demographic and clinical parameters, such as gender, age and length of symptoms. The frequency of psychiatric disorders and the severity of psychiatric symptoms were similar in both groups.

**Conclusion:** BS does not seem to have more psychiatric disorders than HS.

**Fernando Machado Dias<sup>1</sup>,  
Flávia Doyle<sup>2</sup>, Arthur Kummer<sup>1</sup>,  
Francisco Cardoso<sup>2</sup>, Leonardo  
Franklin Fontenelle<sup>3</sup>, Antonio  
Lucio Teixeira<sup>1</sup>**

<sup>1</sup>Neuropsychiatric Branch, Neurology Unit, University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil; <sup>2</sup>Movement Disorders Clinic, Neurology Unit, University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil; and <sup>3</sup>Department of Psychiatry, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Keywords: blepharospasm; dystonia; hemifacial spasm; neuropsychiatry; psychiatric disorders

Antonio Lucio Teixeira, Department of Internal Medicine, School of Medicine, UFMG, Av. Alfredo Balena, 190, Santa Efigênia, Belo Horizonte 30130-100, Brazil.  
Tel/Fax: +55 31 3409 2651;  
E-mail: altextr@gmail.com

## Introduction

Blepharospasm (BS) is one type of focal dystonia. It is characterised by involuntary contractions of the *orbicularis oculi* muscle with subsequent recurrent and involuntary blinking of the eyes. At onset, it appears as an increased frequency of blinking, but it can become quite disabling and even progress to functional blindness (1).

There are growing bodies of evidence linking genetic mutations and dystonia (2). However, neuropathological and pathophysiological aspects underlying dystonia are largely unknown (3,4).

Recent studies have yielded conflicting results regarding the occurrence of non-motor disorders in focal dystonia, such as psychiatric syndromes and cognitive deficits (5–9). These symptoms seem to

support the current model of a dysfunction within corticostriatal circuitry in focal dystonia development (10). The investigation of a possible association between psychiatric disorders and primary dystonia offers the opportunity to clarify this issue, since the brain circuits involved in some psychiatric conditions are already described (11,12). For instance, obsessive-compulsive disorder (OCD) has been consistently associated with striatal abnormalities and, hence, fronto-striatal dysfunction.

Studies assessing systematically psychiatric disorders in focal dystonia are lacking in the literature (13). Nevertheless, psychiatric comorbidities are frequently reported in these patients and seem to be related to significant impact on clinical control and quality of life (14–17).

The aim of this study was to investigate the frequency of psychiatric disorders and the severity of these symptoms in BS patients. For comparison, patients with hemifacial spasm (HS) were recruited. HS is characterised by non-voluntary contractions of the *orbicularis oculi* muscle and may evolve to compromise other muscles of one-half of the face. Although these two conditions are very similar in terms of symptoms and subjective impairment, HS results from peripheral facial nerve damage and is not related to basal ganglia dysfunction (18). Thus, HS constitutes an ideal control group for studies investigating the pathophysiology of non-motor symptoms of BS.

**Methods**

Fifty-one patients followed at the Movement Disorders Clinic of the University Hospital, Federal University of Minas Gerais (UFMG) were included in this study. Written informed consent was obtained from all patients. The study was approved by the local ethics committee.

Twenty-two patients (M/F, 7/15) diagnosed with primary BS participated in the study. A previous careful investigation of secondary or symptomatic causes of dystonia was performed. For comparison, 29 patients with HS (M/F, 7/22) were studied.

Patients underwent neurological and psychiatric examinations. The Mini Mental State Examination (MMSE) was administered to exclude patients with a cognitive performance suggestive of cognitive

decline or dementia (19,20). All patients had been treated with botulinum toxin at least once before the inclusion in this study.

Psychiatric examination included a structured clinical interview for current psychiatric disorders according to *Diagnostic Statistical Manual, fourth edition* (DSM-IV) (MINI-Plus), and psychometric scales, including the Yale-Brown Obsessive Scale (YBOCS) (21), the Beck Depression Inventory (BDI) (22), the Hamilton Rating Scale for Depression (HRSD) (23), the Hamilton Anxiety Scale (HAS) (24) and the Liebowitz Social Anxiety Scale (LSAS) (25).

Comparisons of categorical variables between groups were performed by the Fisher’s exact test. For continuous variables, Mann-Whitney *U* test was used. All *p*-values were two-tailed and a significance level of 0.05 was chosen. Statistical analysis was performed using the SPSS v15.0 software (SPSS Inc., Chicago, IL, USA).

**Results**

Patients with BS or HS did not differ in gender, age, educational level, disease duration or cognitive performance (Table 1). The group of patients with BS was in use of botulinum toxin for a longer period of time than the group of patients with HS (*p* = 0.011).

Table 2 shows the frequency of current psychiatric disorders in both groups. BS and HS patients did not differ in frequency of any disorder. However, the

Table 1. Demographic and clinical features of patients with blepharospasm and those with hemifacial spasm

	Blepharospasm (n = 22)	Hemifacial spasm (n = 29)	<i>p</i> -Value
Gender (M/F)	7/15	7/22	0.752
Age, years, mean ± SD	61.5 ± 13.7	60.5 ± 11.7	0.648
Educational level, years, mean ± SD	6.7 ± 4.8	5.8 ± 3.4	0.445
Marital status, married (%)	12 (55)	19 (66)	0.564
Length of symptoms, years, mean ± SD	8.4 ± 4.8	9.1 ± 4.9	0.985
Smoking habit (%)	3 (14)	2 (7)	0.640
<i>N</i> (%) of patients with comorbid diseases	6 (28)	6 (20)	0.741
Years of botulinum toxin use, mean ± SD	2.23 ± 3.19	2.83 ± 2.32	0.011

Table 2. Frequency of current psychiatric diagnosis in blepharospasm and hemifacial spasm patients

	Blepharospasm (n = 22)	Hemifacial spasm (n = 29)	<i>p</i> -Value
Major depressive disorder (%)	3 (13.6)	4 (13.7)	1.000
Dysthymia (%)	1 (4.5)	3 (10.3)	0.624
Abuse/dependence of alcohol (%)	1 (4.5)	7 (24.1)	0.116
Specific phobia (%)	3 (13.6)	2 (6.8)	0.640
Social phobia (%)	8 (36.3)	7 (24.1)	0.370
General anxiety disorder (%)	4 (18%)	3 (10.3)	0.684
Obsessive-compulsive disorder (%)	3 (13.6)	1 (3.4)	0.303
Other anxiety disorders (%)*	4 (18)	6 (20.6)	1.000

\*Include hypochondria, body dysmorphic disorder, panic disorder, post-traumatic stress disorder.

## Psychiatric disorders in blepharospasm and hemifacial spasm

Table 3. Comparison of scores from blepharospasm and hemifacial spasm patients in different psychometric scales

	Blepharospasm ( <i>n</i> = 22)	Hemifacial spasm ( <i>n</i> = 29)	<i>p</i> -Value
LSAS-anxiety (mean ± SD)	21.1 ± 4.5	18.7 ± 2.8	0.627
LSAS-avoidance (mean ± SD)	23.8 ± 4.5	18.6 ± 2.6	0.689
HAS (mean ± SD)	12.0 ± 2.2	8.4 ± 1.8	0.137
BDI (mean ± SD)	14.0 ± 2.9	11.5 ± 2.4	0.345
HRSD (mean ± SD)	13.1 ± 12.2	11.2 ± 13.5	0.335
YBOCS*, patients with score greater than 1 (%)	4 (18)	1 (3)	0.083

LSAS, Liebowitz Social Anxiety Scale; HAS, Hamilton Anxiety Scale; BDI, Beck Depression Inventory; HRSD, Hamilton Rating Scale for Depression; YBOCS, Yale-Brown Obsessive-Compulsive Scale.

\*As most of the patients did not score in YBOCS, the frequency of patients scoring in this scale was used for comparison (Fisher's exact test).

frequency of major depression and anxiety disorders were remarkably high in both groups. Suicidal ideation was present in 4.5 and 13.7% of BS and HS patients, respectively ( $p = 0.374$ ). None of our patients were diagnosed with psychotic or bipolar disorders.

Also, the frequency of psychiatric drugs did not differ between groups. Three (15.8%) patients with BS and six (26.1%) patients with HS were in the use of antidepressants ( $p = 0.714$ ). Three (15.8%) patients with BS and three (11.5%) patients with HS were in the use of benzodiazepines ( $p = 1.000$ ).

In line with the aforementioned results, the scores in psychometric scales were similar in both groups (Table 3).

### Discussion

According to the current study, patients with BS or HS do not show significant differences in frequency and severity of psychiatric symptoms. Our findings is in contrast with some studies in which anxiety and depressive symptoms were described as more frequent in BS patients than in HS subjects (14,26,27). Hall et al. evaluated 159 BS patients and 91 HS patients by phone call using DSM-IV criteria for the diagnosis of anxiety disorders and the Center of Epidemiologic Studies Depression Scale (CESD) for depression diagnosis (5). They found that BS patients were more prone to symptoms of depression and anxiety than HS patients. Although this study had a large size sample, the absence of a structured clinical interview performed face to face may have influenced the results. We intended to overcome this limitation by using a structured clinical interview and several psychometric scales validated for the Brazilian population (21–25,28).

Some previous studies have focused in obsessive-compulsive phenomena in BS with conflicting results (26,29,30). There are some phenomenological similarities between dystonia and OCD regarding persistent, perseverative, repetitive and involuntary nature of symptoms (31). It has been postulated that

corticostriatal dysfunction is involved in the pathophysiology of the two disorders (32,33). However, Munhoz et al.'s study did not find a higher frequency of OCD in BS patients when compared with patients suffering from HS (30). In the current study, there was a trend for more BS patients to score in the YBOCS (Table 3). YBOCS is considered a reliable method for assessment of OCD symptoms (9). The frequency of OCD in the group of patients with BS was also remarkably high, despite the lack of statistical difference from the HS group. The lack of statistical significance was probably because of the reduced size of the samples.

The duration of botulinum toxin use was significantly longer in BS patients than in HS patients (Table 1). We believe this datum does not prevent the comparison between both groups, since gender, age, educational level, disease duration and disease severity were similar. However, the fact that the administration of botulinum toxin can decrease cortical somatosensory activity warrants mention (34). This observation is relevant because of the new pathophysiological model of dystonia that proposes an original deficit or dysfunction in the somatosensorial cortex (3,35). According to this model, a combination of environmental triggers and genetic predisposition leads to plastic changes in cortical areas. It has been suggested that the repetition of a patterned movement, such as that performed by a professional musician or a writer, may induce plastic changes in the brain altering some cortical functions, including the control of movement, leading to dystonia (36). These plastic changes have been suggested to be extendable to higher cortical areas, such as the ones involved in motor preparation and sensory representation, and thus could interfere in some neuropsychological tasks (37). Indeed, some deficits have been found in the performance of patients with primary dystonia in tasks assessing attentional and executive functions (38). Nevertheless, it is still lacking scientific evidence connecting this pathophysiological model to the higher frequency of some psychiatric disorders in this population. In this case, it seems that

the basal ganglia model still gives the best explanations (38). However, our findings regarding the frequency of psychiatric symptoms in BS do not support these hypotheses.

BS and HS are diseases that cause significant impairment and have serious anti-aesthetic effect. The patients suffer from prejudice and are stigmatised. The observed similar frequency of psychiatric symptoms in both diseases may reflect the difficulty of living with a neurological disease with those characteristics (39,40). Indeed, despite the similar frequency of psychiatric disorders in both BS and HS, we observed that the frequency of some psychiatric disorders, such as major depression and general anxiety disorder, seems to be higher in patients with these diseases than in general population. Previous studies have also noticed an increased frequency of psychiatric disorders in BS (29,41). The lack of a healthy control group in our study and its small sample size prevents definitive conclusions. Moreover, patients were recruited in a tertiary centre, where patients with a more severe disease are usually referred to. Altogether, these limitations may have some implication in the external validity of our study.

In conclusion, patients with BS do not seem to have more psychiatric disorders than those with HS. This observation helps to elucidate the great controversy that exists in the literature concerning the frequency of psychiatric symptoms in dystonia. The fact that primary dystonia is a rare disease and patients are usually attended in tertiary centres turns difficult the development of studies with adequate sample size and controls group. The little knowledge about other aspects of primary dystonia prevents the best approach to the disease. An additional work with proper methodology investigating the neuroimaging, immunology, genetics, neuropathology and clinical aspects of BS is necessary.

## References

1. DEFAZIO G, ABBRUZZESE G, LIVREA P, BERARDELLI A. Epidemiology of primary dystonia. *Lancet Neurol* 2004;**3**: 673–678.
2. DE CARVALHO AGUIAR PM, OZELIUS LJ. Classification and genetics of dystonia. *Lancet Neurol* 2002;**1**:316–325.
3. LIU X, YIANNI J, WANG S, BAIN PG, STEIN JF, AZIZ TZ. Different mechanisms may generate sustained hypertonic and rhythmic bursting muscle activity in idiopathic dystonia. *Exp Neurol* 2006;**198**:204–213.
4. HOLTON JL, SCHNEIDER SA, GANESHARAJAH T et al. Neuropathology of primary adult-onset dystonia. *Neurology* 2008;**70**:695–699.
5. TINAZZI M, ROSSO T, FIASCHI A. Role of the somatosensory system in primary dystonia. *Mov Disord* 2003;**18**: 605–622.
6. BÜTTNER T, KUHN W, DIETZ M et al. Impaired visual function in focal idiopathic dystonia. *Eur Neurol* 1999;**41**: 94–98.
7. LELOW B, STÜBINGER C. Visuospatial functions in patients with spasmodic torticollis. *Percept Mot Skills* 1994;**78**: 1363–1375.
8. HINSE P, LELOW B, HUMBERT T, LAMPARTER U, JUNGE A, EMSKÖTTER T. Impairment of visuospatial function in idiopathic spasmodic torticollis. *J Neurol* 1996;**243**:29–33.
9. DIAS FMV, DOYLE FCP, KUMMER A, CARDOSO F, CAMELLI P, TEIXEIRA AL. Executive functioning in patients with blepharospasm in comparison with patients with hemifacial spasm. *Arq Neuropsiquiatr* 2009;**67**:12–15.
10. BERARDELLI A, ROTHWELL JC, HALLETT M, THOMPSON PD, MANFREDI M, MARSDEN CD. The pathophysiology of primary dystonia. *Brain* 1998;**121**:1195–1212.
11. INSEL TR. Toward a neuroanatomy of obsessive compulsive disorder. *Arch Gen Psychiatry* 1992;**49**:739–744.
12. DIAS FMV, HOUNIE AG, CORRÊA H, TEIXEIRA AL. Primary dystonia and obsessive-compulsive disorder. *J Bras Psiquiatr* 2007;**56**:60–63.
13. DAUER WT, BURKE RE, GREENE P, FAHN S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. *Brain* 1998;**121**:547–560.
14. HALL TA, MCGWIN G Jr, SEARCEY K et al. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. *Arch Ophthalmol* 2006;**124**:116–119.
15. KUBOTA Y, MURAI T, OKADA T et al. Obsessive-compulsive characteristics in patients with writer's cramp. *J Neurol Neurosurg Psychiatry* 2001;**71**:413–414.
16. BIHARI K, HILL JL, MURPHY DL. Obsessive-compulsive characteristics in patients with idiopathic spasmodic torticollis. *Psychiatry Res* 1992;**42**:267–272.
17. GÜNDEL H, WOLF A, XIDARA V et al. High psychiatric comorbidity in spasmodic torticollis: a controlled study. *J Nerv Ment Dis* 2003;**191**:465–473.
18. NIELSEN VK. Pathophysiology of hemifacial spasm. I: ephaptic transmission and ectopic excitation. *Neurology* 1984;**34**:418–426.
19. FOLSTEIN MF, ROBINS LN, HELZER JE. Mini Mental State Examination (MMSE). *Arch Gen Psychiatry* 1983;**40**:812.
20. BRUCKI SM, NITRINI R, CAMELLI P, BERTOLUCCI PH, OKAMOTO IH. Suggestions for utilization of the minimal mental state examination in Brazil. *Arq Neuropsiquiatr* 2003;**61**:777–781.
21. ASBAHR FR. Escalas de avaliação de transtorno obsessivo compulsivo na infância e adolescência. *Rev Psiquiatr Clin* 1998;**25**:310–319.
22. GORENSTEIN C, ANDRADE L. Inventário de Depressão de Beck: propriedades psicométricas da versão em português. *Rev Psiquiatr Clín* 1998;**25**:245–250.
23. MORENO RA, MORENO DH. Escalas de Avaliação para Depressão de Hamilton (HAM-D) e Montgomery-Asberg (MADRS). In: GORENSTEIN C, ANDRADE LHS, ZUARDI AW, eds. Escalas de avaliação clínica em psiquiatria e psicofarmacologia. São Paulo: Lemos-Editorial, 2000: 65–87.
24. LIMA MG. Avaliação dos níveis de ansiedade através da Escala de Hamilton em pacientes submetidos a psicoterapia breve grupal dinâmica associada a medicação e sem associação medicamentosa. *J Bras Psiquiatr*. 1993;**42**: 381–386.

## Psychiatric disorders in blepharospasm and hemifacial spasm

25. TERRA MB, BARROS HM, STEIN AT et al. Internal consistency and factor structure of the Portuguese version of the Liebowitz Social Anxiety Scale among alcoholic patients. *Rev Bras Psiquiatr* 2006;**28**:265–269.
26. BROOKS A, THIEL A, ANGERSTEIN D, DRESSLER D. Higher prevalence of obsessive compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm. *Am J Psychiatry* 1998;**155**:555–557.
27. SCHEIDT CE, SCHULLER B, RAYKI O, KOMMERELL G. Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm. *Neurology* 1996;**47**:43–45.
28. AMORIM P. Mini-International Neuropsychiatric Interview (Mini): validação de entrevista breve para diagnóstico de transtornos mentais. *Rev Bras Psiquiatr* 2000;**22**:106–115.
29. BIHARI K, PIGTT TA, HILL JL, MURPHY DL. Blepharospasm and obsessive compulsive disorder. *J Nerv Ment Dis* 1992;**180**:130–132.
30. MUNHOZ RP, TEIVE HA, DELLA COLETTA MV et al. Frequency of obsessive compulsive symptoms in patients with blepharospasm and hemifacial spasm. *Arq Neuropsiquiatr* 2005;**63**:213–216.
31. CAVALLARO R, GALARDI G, CAVALLINI MC et al. Obsessive compulsive disorder among idiopathic focal dystonia patients: an epidemiological and family study. *Biol Psychiatry* 2002;**52**:356–361.
32. JENIKE MA. Obsessive-compulsive disorder. *N Engl J Med* 2004;**350**:259–265.
33. HALLETT M. Blepharospasm: recent advances. *Neurology* 2002;**59**:1306–1312.
34. PELLER M, ZEUNER KE, MUNCHAU A et al. The basal ganglia are hyperactive during discrimination of tactile stimuli in writer's cramp. *Brain* 2006;**129**:2697–2708.
35. ABBRUZZESE G, MARCHESE R, BUCCOLIERI A, GASPARETTO B, TROMPETTO C. Abnormalities of sensorimotor integration in focal dystonia: a transcranial magnetic stimulation study. *Brain* 2001;**124**:537–545.
36. STEFAN K, KUNESCH E, BENECKE R, CLASSEN J. Induction of plasticity in the human motor cortex by paired associative stimulation. *Brain* 2000;**123**:572–584.
37. BERG D, HERMANN MJ, MULLER TJ et al. Cognitive response control in writer's cramp. *Eur J Neurol* 2001;**8**:587–594.
38. SCOTT RB, GREGORY R, WILSON J et al. Executive cognitive deficits in primary dystonia. *Mov Disord* 2003;**18**:539–550.
39. PHELAN J, LINK B, DOVIDIO J. Stigma and prejudice: one animal or two? *Soc Sci Med* 2008;**67**:358–367.
40. GARCIA JA, CROCKER J. Reasons for disclosing depression matter: the consequences of having egosystem and ecosystem goals. *Soc Sci Med* 2008;**67**:453–462.
41. WENZEL T, SCHNIDER P, GRIENGL H, BIRNER P, NEPP J, AUFF E. Psychiatric disorders in patients with blepharospasm – a reactive pattern? *J Psychosom Res* 2000;**48**:589–591.